Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

s substitutes for ev3's net income (loss), ev3's peripheral vascular net sales or ev3's net income (loss) per share, respectively, each as prepared in accordance with GAAP. In addition, investors should note that any non-GAAP financial measures used by ev3 may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as that of other companies. Whenever ev3 uses historical non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measure. A reconciliation of ev3's EBITDA, excluding charges for non-cash stock-based compensation, to ev3's net loss prepared in accordance with GAAP can be found immediately following the detail of net sales by geography later in this press release. This information is also made available on the company's website at http://www.ev3.net. ev3, however, does not provide forward-looking guidance for certain financial data, such as depreciation, accretion, net income (loss), net income (loss) per common share and as a result, is not able to provide a reconciliation of GAAP to non-GAAP financial measures for forward-looking data. In particular, ev3 is providing adjusted earnings (loss) per share guidance in this release only on a non-GAAP basis due to the inherent uncertainties associated with forecasting the timing and amount of restructuring, impairment and other unusual and infrequent items associated with its acquisition of FoxHollow.

ev3 Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share amounts)

(unaudited)


'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... Outside GC, the leading provider of on-demand, in-house ... Casey as a member of the firm, further strengthening ... , Debbie has spent over 20 years in the ... North America in both legal and business capacities. ... Outside GC’s growing list of healthcare clients, with a ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Realty Trust, Inc.,(NYSE: BMR ) today announced the tax treatment of its 2007 distributions as,follows:, ... CUSIP: 09063H107 ... Total ... Taxable Ordinary Date Date ...
... Inc.,(NYSE: BMR ) today announced it will report results ... the market closes on Thursday,February 28, 2008., Alan D. ... Officer, will host an investor conference call at 10:00,a.m. Pacific ... results and operations for the year., The call will ...
... , RICHMOND, VA, January 29 ... interview with Insmed Therapeutic Proteins President,Steve Glover ... industry is good for,patients and can stem ... from biotechnology. The American Magazine is the ...
Cached Biology Technology:BioMed Realty Trust Announces Tax Treatment of 2007 Distributions 2BioMed Realty Trust Announces Tax Treatment of 2007 Distributions 3BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results 2Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine 2Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine 3
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... , Every year the approach of flu season sets off ... are many different strains of flu and they vary from ... educated guess and tell manufacturers which variants of the flu ... works, flu-related illnesses can kill 3,000 to 49,000 Americans annually, ...
... the Polytechnic Institute of New York University (NYU-Poly) and ... carrier in their lab that is five times more ... delivery methodsreagent vectors. This novel complex is a peptide-polymer ... are used to carry DNA into cells. ...
... is a devastating illness that gradually robs sufferers of muscle ... drug available to treat the disease extends life spans by ... study published in Nature Genetics , University of Pennsylvania ... which ALS acts. Working with a powerful fruit fly model ...
Cached Biology News:Stanford researchers take a step toward developing a 'universal' flu vaccine 2Stanford researchers take a step toward developing a 'universal' flu vaccine 3Stanford researchers take a step toward developing a 'universal' flu vaccine 4Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells 2Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 2Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 3Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 4